HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures - Archive ouverte HAL Access content directly
Journal Articles Nature Medicine Year : 2017

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures

(1) , (1) , (1) , (1, 2) , (3) , (1) , (4, 1) , (1) , (5) , (6) , (7) , (8) , (1) , (9) , (10) , (3) , (1) , (11) , (12) , (13, 14) , (6) , (15) , (16) , (10, 17) , (18) , (19) , (20) , (21) , (22, 23) , (24, 25) , (1) , (1) , (26, 1)
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
Sandrine Boyault
  • Function : Author
  • PersonId : 757688
  • IdRef : 075706466
Gu Kong
  • Function : Author
Åke Borg
  • Function : Author
Christos Sotiriou
Steven van Laere

Abstract

Approximately 1–5% of breast cancers are attributed to inherited mutations in BRCA1 or BRCA2 and are selectively sensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. In other cancer types, germline and/or somatic mutations in BRCA1 and/or BRCA2 (BRCA1/BRCA2) also confer selective sensitivity to PARP inhibitors. Thus, assays to detect BRCA1/BRCA2-deficient tumors have been sought. Recently, somatic substitution, insertion/deletion and rearrangement patterns, or 'mutational signatures', were associated with BRCA1/BRCA2 dysfunction. Herein we used a lasso logistic regression model to identify six distinguishing mutational signatures predictive of BRCA1/BRCA2 deficiency. A weighted model called HRDetect was developed to accurately detect BRCA1/BRCA2-deficient samples. HRDetect identifies BRCA1/BRCA2-deficient tumors with 98.7% sensitivity (area under the curve (AUC) = 0.98). Application of this model in a cohort of 560 individuals with breast cancer, of whom 22 were known to carry a germline BRCA1 or BRCA2 mutation, allowed us to identify an additional 22 tumors with somatic loss of BRCA1 or BRCA2 and 47 tumors with functional BRCA1/BRCA2 deficiency where no mutation was detected. We validated HRDetect on independent cohorts of breast, ovarian and pancreatic cancers and demonstrated its efficacy in alternative sequencing strategies. Integrating all of the classes of mutational signatures thus reveals a larger proportion of individuals with breast cancer harboring BRCA1/BRCA2 deficiency (up to 22%) than hitherto appreciated (~1–5%) who could have selective therapeutic sensitivity to PARP inhibition.
Fichier principal
Vignette du fichier
davies2017.pdf (1.39 Mo) Télécharger le fichier
Origin : Files produced by the author(s)
Loading...

Dates and versions

hal-01525050 , version 1 (12-07-2017)

Identifiers

Cite

Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, et al.. HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures. Nature Medicine, 2017, 23 (4), pp.517 - 525. ⟨10.1038/nm.4292⟩. ⟨hal-01525050⟩
766 View
571 Download

Altmetric

Share

Gmail Facebook Twitter LinkedIn More